Cost-effectiveness of early treatment with first-line NNRTI-based HARRT regimens in the UK, 1996-2006

PLoS ONE

Volumn 6, Issue 5, 2011, Pages

  Beck, Eduard J ^a,b,m   Mandalia, Sundhiya ^a,c,m   Lo, Gary ^a,m   Sharott, Peter ^d   Youle, Mike ^a,e   Anderson, Jane ^f   Baily, Guy ^g   Brettle, Ray ^h   Fisher, Martin ⁱ   Gompels, Mark ^j   Kinghorn, George ^k   Johnson, Margaret ^e   McCarron, Brendan ^l   Pozniak, Anton ^m   Tang, Alan ⁿ   Walsh, John ^o   White, David ^p   Williams, Ian ^q   Gazzard, Brian ^a,c,m   NPMS HHC Steering Group, ^r  

^a NPMS HHC Coordinating and Analytic Centre   (United Kingdom)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

^d London Specialised Commissioning Group   (United Kingdom)

^e ROYAL FREE HOSPITAL   (United Kingdom)

^f HOMERTON UNIVERSITY HOSPITAL   (United Kingdom)

^g ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^h WESTERN GENERAL HOSPITAL   (United Kingdom)

ⁱ ROYAL SUSSEX COUNTY HOSPITAL   (United Kingdom)

^j SOUTHMEAD HOSPITAL   (United Kingdom)

^k ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

^l JAMES COOK UNIVERSITY HOSPITAL   (United Kingdom)

^m CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

ⁿ ROYAL BERKSHIRE HOSPITAL   (United Kingdom)

^o ST MARY S HOSPITAL   (United Kingdom)

^p Birmingham Heartsland Hospital   (United Kingdom)

^q UNIVERSITY COLLEGE LONDON   (United Kingdom)

^r NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; AFRICAN AMERICAN; ARTICLE; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG TREATMENT FAILURE; EARLY INTERVENTION; FEMALE; HEALTH CARE COST; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PUBLIC HEALTH SERVICE; UNITED KINGDOM; ALGORITHM; ECONOMICS; METHODOLOGY; MIDDLE AGED; OUTCOME ASSESSMENT; STATISTICS; SURVIVAL; TIME;

ADULT; ALGORITHMS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; COST-BENEFIT ANALYSIS; FEMALE; GREAT BRITAIN; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); REVERSE TRANSCRIPTASE INHIBITORS; SURVIVAL ANALYSIS; TIME FACTORS;

EID: 79957508182     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0020200     Document Type: Article

References (36)

1. Mandalia S, Mandalia R, Lo G, Chadborn T, Sharott P, et al. (2010) Rising Population Cost for Treating People Living with HIV in the UK, 1997-2013. PLoS ONE 5 (12): e15677 doi:10.1371/journal.pone.0015677.
2. Beck EJ, Mandalia S, Youle M, Brettle R, Fisher M, et al. (2008) Treatment Outcome and Cost-effectiveness of different HAART Regimens in the UK 1996-2002. International Journal of STD & AIDS 19: 297-304.
3. UNAIDS/PEPFAR. (2007) Interim Guidelines on Protecting the Confidentiality and Security of HIV information: Proceedings from a Workshop, 15-17 May 2006, Geneva, Switzerland. 15 May http://data.unaids.org/pub/manual/2007/confidentiality_security_interim_guidelines_15may2007_en.pdf Accessed 2-5-2011.
4. Beck EJ, Mandalia S, (2003) The Cost of HIV Treatment and Care in England since HAART: Part 1. British Journal of Sexual Medicine 27 (1): 19-21.
5. Beck EJ, Mandalia S, (2003) The Cost of HIV Treatment and Care in England since HAART: Part 2. British Journal of Sexual Medicine 27 (2): 21-23.
6. Beck EJ, Tolley K, Power A, Rutter P, Izumi J, et al. (1998) Use and cost of HIV service provision in England. Pharmacoeconomics 14: 639-52.
7. Beck EJ, Mandalia S, Williams I, Power A, Newson R, et al. (1999) Decreased morbidity and use of hospital services in English HIV infected individuals with increased uptake of anti-retroviral therapy 1996 - 1997. AIDS; 13: 2157-64.
8. Mandalia S, Parmar D, Fisher M, Pozniak A, Tang A, et al. (2002) Naïvely Changing HAART. HIV Medicine 3: 254-262.
9. Beck EJ, Mandalia S, Lo G, Youle M, Gazzard B, (2008) Use and Cost of HIV Service Provision in UK NPMS-HHC Sites: Aggregate Analyses January 1996 to December 2006. London, UK NPMS-HHC Coordinating and Analytic Centre, St.Stephen's Centre, Chelsea and Westminster Hospital Trust.
10. Beck EJ, Miners AH, (2001) Effectiveness and Efficiency in the Delivery of HIV Services: economic and related considerations in The Effective Management of HIV Disease,In: Gazzard B, Johnson M, Miles A, editors. London Aesculapius Medical Press pp. 113-38.
11. Brouwer WBF, Niessen LW, Postma MJ, Rutten FFH, (2005) Need for differential discounting of costs and health effect in cost-effectiveness analyses. BMJ 331: 446-8.
12. Thakkar B, Hur K, Henderson WG, Oprian C, (1998) A Method to Generate Kaplan-Meier and Adjusted Survival Curves using SAS. SUGI 23, Paper 226, March 22-25, Nashville, USA. http://www2.sas.com/proceedings/sugi23/Stats/p226.pdf Accessed 2-5-2011.
13. Beck EJ, Mandalia S, Gaudreault M, Brewer C, Zowall H, et al. (2004) The Cost-effectiveness of HAART, Canada 1991-2001. AIDS 18: 2411-9.
14. Badri M, Maartens G, Mandalia S, Bekker L-G, Penrod JR, et al. (2006) Cost-effectiveness of Highly Active Antiretroviral Therapy in South Africa. Plos Medicine January 3: e4.
15. Beck EJ, Mandalia S, Lo G, Sharott P, Youle M, et al. (2010) PIboosted or NNRTI as first-line HAART regimens? Lessons from the UK.XVIII International AIDS Conference, Vienna, Austria 18-23 July, Abstract THPE0084.
16. Rawlings MD, Culyer AJ, (2004) National institute for Clinical Excellence and its value judgements. BMJ 329: 224-227.
17. Beck EJ, Mays N, (2006) Some Lessons Learned In: Beck EJ, Mays N, Whiteside A, Zugina J, editors. The HIV Pandemic: local and global implications. Oxford, UK Oxford University Press pp. 769-772.
18. Krentz HB, Gill MJ, (2008) Cost of medical care for HIV-infected patients within a regional population from 1997 to 2006. HIV Medicine 9: 721-30.
19. John A, Fleishman JA, Yehia BR, Moore RD, Gebo KA, et al. (2010) The Economic Burden of Late Entry Into Medical Care for Patients With HIV Infection. Medical Care 48: 1071-9.
20. Hogg RS, Yip B, Chan KJ, Wood E, Craib KJP, et al. (2001) Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy. JAMA 286: 2568-77.
21. Wood E, Hogg B, Yip B, Harrigan PR, O'Shaughenessy MV, et al. (2003) Is there a baseline CD4 cell count that precludes a survival response to modern antiretroviral therapy? AIDS 17: 711-720.
22. When To Start Consortium. (2009) Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet 373: 1352-63.
23. Gazzard BG on behalf of the BHIVA Treatment Guidelines Writing Group (2008) British HIV Association guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008. HIV Medicine 9: 563-608.
24. WHO (2010) Antiretroviral therapy for HIV infection in adults and adolescents, Recommendations for a public health approach, 2010 revision. Geneva, Switzerland. http://whqlibdoc.who.int/publications/2010/9789241599764_eng.pdf. Accessed 2-5-2011.
25. Hammer SM, Eron JJ Jr, Reiss P, Schooley RT, Thompson MA, et al. (2008) Antiretroviral Treatment of Adult HIV Infection: 2008 Recommendations of the IAS-USA. JAMA 300: 555-570.
26. Panel on Antiretroviral Guidelines for Adults and Adolescents. (2009) Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. December 1; 1-161. http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf Accessed 2-5-2011.
27. INSIGHT Community Advisory Board. (2010) Community statement on the START trial and the change in the US DHHS treatment guidelines May 4. http://www.tac.org.za/community/node/2861 Accessed 2-5-2011.
28. Crum-Cianflone NF, Grandits G, Echols S, Ganesan A, Landrum M, et al. (2010) Trends and Causes of Hospitalizations Among HIV-Infected Persons During the Late HAART Era: What Is the Impact of CD4 Counts and HAART Use? J Acquir Immune Defic Syndr 54: 248-257.
29. Neaton JD, Babiker A, Emery S, Gordin F, Lundgren J, et al. (2009) Strategic Timing of Antiretroviral Treatment (START) http://clinicaltrials.gov/ct2/show/NCT00867048 Accessed 2-5-2011.
30. Geng EH, Bwana MB, Kabakyenga J, Muyindike W, Emenyonu NI, et al. (2010) Diminishing Availability of Publicly Funded Slots for Antiretroviral Initiation among HIV-Infected ART-Eligible Patients in Uganda. PLoS ONE 5 (11): e14098 doi:10.1371/journal.pone.0014098.
31. Granich RM, Gilks CF, Dye C, De Cock KM, Williams BG, (2009) Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet 373: 48-57.
32. Wagner B, Blower S, (2010) Costs of eliminating HIV in South Africa have been underestimated. Lancet 376: 953-4.
33. Lina Josefsson L, Dahl V, Palmer S, (2010) Can HIV infection be eradicated through use of potent antiviral agents? Current Opinion in Infectious Diseases, 2010 23: 628-632.
34. Ford N, Mills E, Calmy A, (2009) Rationing Antiretroviral Therapy in Africa - Treating Too Few, too Late. N Engl J Med 360: 1808-10.
35. Long E, Brandeau M, Owens D, (2010) The Cost-Effectiveness and Population outcomes of Expanded Screening and Antiretroviral Treatment in the US. Ann. Inter. Med 153: 778-89.
36. Beck EJ, Walensky RP, (2008) The Outcome and Impact of Ten Years of HAART. A Decade of HAART Oxford, UK Oxford University Press pp. 45-62.